An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)
NCT01093105 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-06-03
Summary
The objective of this study is to evaluate the natural history of disease progression in infants with globoid cell leukodystrophy (GLD).
Conditions
- Leukodystrophy, Globoid Cell
Sponsors & Collaborators
-
PharmaNet
collaborator INDUSTRY -
Nextrials, Inc.
collaborator INDUSTRY -
Shire
lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Max Age
- 21 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-01
- Primary Completion
- 2012-05-01
- Completion
- 2012-05-01
More Related Trials
-
Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor
NCT03328858 ·Status: TERMINATED ·Phase: NA
-
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
NCT06184503 ·Status: RECRUITING
-
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
NCT02187809 ·Status: TERMINATED ·Phase: PHASE3
-
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
NCT02174094 ·Status: WITHDRAWN ·Phase: PHASE3
-
Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis
NCT01399047 ·Status: COMPLETED ·Phase: PHASE2
-
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
NCT05462054 ·Status: WITHDRAWN
-
Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT03922594 ·Status: TERMINATED
-
Management of Myelomeningocele Study (MOMS)
NCT00060606 ·Status: COMPLETED ·Phase: NA
-
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
NCT02036853 ·Status: COMPLETED ·Phase: PHASE2
-
Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance
NCT06075485 ·Status: RECRUITING
-
Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy
NCT02261753 ·Status: TERMINATED ·Phase: NA
-
Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients
NCT00723762 ·Status: COMPLETED
-
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
NCT05590884 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee
NCT05391841 ·Status: WITHDRAWN
-
A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
NCT06422377 ·Status: TERMINATED ·Phase: PHASE3
-
Predictors of Drug Resistant Epilepsy Among Pediatric Patients
NCT07241754 ·Status: NOT_YET_RECRUITING
-
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
NCT06309251 ·Status: RECRUITING
-
Ultra High Field MRI of Focal Pediatric Epilepsy
NCT03318237 ·Status: TERMINATED
-
A Multicenter Selective Screening Study to Investigate the Frequency of Neuronal Ceroid Lipofuxinosis Type 2 (CLN2)
NCT06128226 ·Status: RECRUITING
-
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
NCT02829827 ·Status: TERMINATED ·Phase: PHASE2
-
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial
NCT01619644 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome
NCT02023424 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome
NCT00272844 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
NCT04448873 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
NCT07285005 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3